Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood

Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained r...

Descripción completa

Detalles Bibliográficos
Autores principales: Günther, Claudia, Wolf, Christine, Fennen, Louisa, Rösing, Sarah, Beissert, Stefan, Aringer, Martin, Lee-Kirsch, Min Ae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551165/
https://www.ncbi.nlm.nih.gov/pubmed/37809086
http://dx.doi.org/10.3389/fimmu.2023.1253279
_version_ 1785115702527524864
author Günther, Claudia
Wolf, Christine
Fennen, Louisa
Rösing, Sarah
Beissert, Stefan
Aringer, Martin
Lee-Kirsch, Min Ae
author_facet Günther, Claudia
Wolf, Christine
Fennen, Louisa
Rösing, Sarah
Beissert, Stefan
Aringer, Martin
Lee-Kirsch, Min Ae
author_sort Günther, Claudia
collection PubMed
description Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained remission of previously refractory CLE lesions, beginning within the first weeks of treatment. Decline in CLASI-A score was paralleled by a reduction in IFN score determined by mRNA expression of seven IFN-stimulated genes (ISGs) in blood. These data suggest that a subset of ISGs could be a valuable biomarker in CLE.
format Online
Article
Text
id pubmed-10551165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105511652023-10-06 Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood Günther, Claudia Wolf, Christine Fennen, Louisa Rösing, Sarah Beissert, Stefan Aringer, Martin Lee-Kirsch, Min Ae Front Immunol Immunology Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained remission of previously refractory CLE lesions, beginning within the first weeks of treatment. Decline in CLASI-A score was paralleled by a reduction in IFN score determined by mRNA expression of seven IFN-stimulated genes (ISGs) in blood. These data suggest that a subset of ISGs could be a valuable biomarker in CLE. Frontiers Media S.A. 2023-09-21 /pmc/articles/PMC10551165/ /pubmed/37809086 http://dx.doi.org/10.3389/fimmu.2023.1253279 Text en Copyright © 2023 Günther, Wolf, Fennen, Rösing, Beissert, Aringer and Lee-Kirsch https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Günther, Claudia
Wolf, Christine
Fennen, Louisa
Rösing, Sarah
Beissert, Stefan
Aringer, Martin
Lee-Kirsch, Min Ae
Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
title Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
title_full Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
title_fullStr Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
title_full_unstemmed Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
title_short Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
title_sort case report: response of cutaneous lupus lesions in sle to interferon receptor blockade parallels reduction of interferon score in blood
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551165/
https://www.ncbi.nlm.nih.gov/pubmed/37809086
http://dx.doi.org/10.3389/fimmu.2023.1253279
work_keys_str_mv AT guntherclaudia casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood
AT wolfchristine casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood
AT fennenlouisa casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood
AT rosingsarah casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood
AT beissertstefan casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood
AT aringermartin casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood
AT leekirschminae casereportresponseofcutaneouslupuslesionsinsletointerferonreceptorblockadeparallelsreductionofinterferonscoreinblood

Ejemplares similares